- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04758351
Prospective Study on the Evaluation, Patient Reported Outcomes and Effectiveness of Treatment for Chronic Cough (PROCOUGH)
Prospective Study on the Evaluation, Patient Reported Outcomes and Effectiveness of Treatment for Chronic Cough in Secondary Care
Study Overview
Detailed Description
This is a prospective observational single-center study of patients referred to secondary care for investigation and management of explained chronic cough, refractory chronic cough, and unexplained chronic cough. The study will have 4 research visits integrated between standard clinical visits. Patients will be recruited from secondary care clinics. Patient eligibility will be assessed against the study inclusion/exclusion criteria and patients will undergo informed consent in the research centre. Subjects who provide informed consent and are enrolled in the study will undergo screening procedures.
At Visit 1 (screening) data on demographics and medical history will be collected and a complete physical examination will be conducted. Subjects will undergo skin prick testing and spirometry and complete self-reported questionnaires (Leicester Cough Questionnaire, Valuation of Lost Productivity, Work Productivity, Activity, and Impairment, Healthcare Resource Utilization, Reflux Disease Questionnaire, Sino-Nasal Outcome Test, and Global Rating of Change Scale). Subjects will be fitted with a 24-hour cough monitor.
At Visit 2, the 24-hour cough monitor will be removed. Subjects will undergo blood sampling, methacholine challenge, sputum induction, and provide a urine sample.
Between Visits 2 and 3, physicians will provide a single clinical treatment pathway to address the most likely cause of chronic cough. Treatment for chronic cough will be in line with current clinical practice guidelines published by the European Respiratory Society Taskforce on Chronic Cough. Treatment plans will range from 2 weeks to 3 months.
Visit 3 will occur 2 weeks to 3 months following subjects' second clinical visit. Subjects will complete self-reported questionnaires (Leicester Cough Questionnaire, Valuation of Lost Productivity, Work Productivity, Activity, and Impairment, Reflux Disease Questionnaire, Sino-Nasal Outcome Test, and Global Rating of Change Scale) and be fitted with a 24-hour cough monitor.
At Visit 4 the 24-hour cough monitor will be removed. Subjects will undergo blood sampling, sputum induction, and provide a urine sample. Subjects will complete a patient satisfaction survey.
All study procedures will be performed according to local standard operating procedures and be conducted by trained and experienced staff with supervision by medical doctors. Safety will be assessed throughout the study by monitoring for adverse events and serious adverse events.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Imran Satia, MD, PhD
- Phone Number: 76228 905-521-2100
- Email: satiai@mcmaster.ca
Study Contact Backup
- Name: Paul O'Byrne, MD
- Phone Number: 76373 905-521-2100
- Email: obyrnep@mcmaster.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4L8
- Recruiting
- Imran Satia
-
Contact:
- Imran Satia, MD PhD
- Email: satiai@mcmaster.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged ≥18-75
- Patients referred to a specialist primarily with a history of chronic cough (cough lasting >8 weeks)
- Normal Chest X-ray
- No Evidence of Airflow Obstruction
Exclusion Criteria:
- Subjects who are currently established on treatment and their chronic cough is well controlled.
- Unable to perform acceptable and reproducible spirometry.
- Current smoker or ex-smoker with ≥20 pack-year smoking history and abstinence of ≤6 months
- Symptoms of upper respiratory tract infection in the last 1 month which have not resolved
- Lower respiratory tract infection or pneumonia in the last 1 month
- Asthma exacerbation in the previous month requiring an increase or start of an inhaled corticosteroid or oral corticosteroid
- Significant other primary pulmonary disorders in particular; pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, significant radiologically proven emphysema, interstitial lung disease or bronchiectasis.
- Any centrally acting medication within the last 2 weeks which in the view of the investigator could influence the coughing. Any participant who is taking amitriptyline, dextromethorphan, pregabalin, gabapentin or opioids will not be eligible to take part in this study unless they are willing and medically able to withdraw from such medication before the start of visit 1. The reason for this is that centrally-acting medications may influence coughing rates at baseline.
- History of psychiatric illness, drug or alcohol abuse which may interfere in the participation of the trial.
- Positive Covid-19 test within 2 weeks of screening visit.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cases - Patients with chronic cough
Patients referred to secondary care clinic for investigation and treatment for explained chronic cough, refractory chronic cough, and unexplained chronic.
|
Based on European Respiratory Society guidelines on management for chronic cough.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in objective cough frequency
Time Frame: 3 months
|
Change in objective cough frequency pre- and post-treatment among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation in change of objective cough frequency and healthcare utilization
Time Frame: 3 months
|
Correlation between pre- and post-treatment change in objective cough frequency and Healthcare Related Utilization among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Healthcare utilization is measured by recording the number of visits to family physician, outpatient specialist, number of tests, and medication use.
|
3 months
|
Correlation in change of objective cough frequency and lost productivity
Time Frame: 3 months
|
Correlation between pre- and post-treatment change in objective cough frequency and lost productivity among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Lost productivity is measured using the Valuation of Lost Productivity questionnaire which contains a series of questions that evaluate the impact of functional impairment on productivity loss, not just for the individual but also on the work environment.
|
3 months
|
Correlation in change of objective cough frequency and work productivity and activity
Time Frame: 3 months
|
Correlation between pre- and post-treatment change in objective cough frequency and work productivity and activity among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Work productivity and activity is measured using the Work Productivity and Activity Impairment Questionnaire which is a 6-item self-administered questionnaire used to assess productivity and impairment because of a specific health problem such as chronic cough.
|
3 months
|
Correlation in change of quality of life and healthcare utilization
Time Frame: 3 months
|
Correlation between pre- and post-treatment change in quality of life and Healthcare Related Utilization among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Quality of life is measured using the Leicester Cough Questionnaire.
The Leicester Cough Questionnaire is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Healthcare utilization is measured by recording the number of visits to family physician, outpatient specialist, number of tests, and medication use.
|
3 months
|
Correlation in change of quality of life and lost productivity
Time Frame: 3 months
|
Correlation between pre- and post-treatment change in quality of life and lost productivity among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Quality of life is measured using the Leicester Cough Questionnaire.
The Leicester Cough Questionnaire is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Lost productivity is measured using the Valuation of Lost Productivity questionnaire which contains a series of questions that evaluate the impact of functional impairment on productivity loss, not just for the individual but also on the work environment.
|
3 months
|
Correlation in change of quality of life and work productivity and activity
Time Frame: 3 months
|
Correlation between pre- and post-treatment change in quality of life and work productivity and activity among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Quality of life is measured using the Leicester Cough Questionnaire.
The Leicester Cough Questionnaire is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
Work productivity and activity is measured using the Work Productivity and Activity Impairment Questionnaire which is a 6-item self-administered questionnaire used to assess productivity and impairment because of a specific health problem such as chronic cough.
|
3 months
|
Patient satisfaction
Time Frame: 3 months
|
Patient satisfaction measurements of clinical investigations, treatment, and use of questionnaires among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Patient satisfaction will be measured using a 5 point Likert scale where the minimum value is 1 indicating participants were very unsatisfied and the maximum value is 5 indicating participants were very satisfied.
|
3 months
|
Comparison of change in objective cough frequency and quality of life
Time Frame: 3 months
|
Comparison of pre- and post treatment change in objective cough frequency and quality of life among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Quality of life is measured using the Leicester Cough Questionnaire.
The Leicester Cough Questionnaire is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
|
3 months
|
Comparison of change in objective cough frequency and participant perceived change in condition
Time Frame: 3 months
|
Comparison of pre- and post-treatment change in objective cough frequency and perceived change in condition among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Perceived change in condition is measured using the Global Rating of Change Scale which is a 15 value scale.
The Global Rating of Change Scale is a 15 point scale with a minimum value of -7 indicating a worse outcome and a maximum value of +7 indicating a better outcome.
|
3 months
|
Measure the relationship between objective cough frequency and lost productivity
Time Frame: 3 months
|
Measure the post treatment relationship between objective cough frequency and lost productivity among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Lost productivity is measured using the Valuation of Lost Productivity questionnaire which contains a series of questions that evaluate the impact of functional impairment on productivity loss, not just for the individual but also on the work environment.
|
3 months
|
Measure the relationship between objective cough frequency and work productivity and activity
Time Frame: 3 months
|
Measure the post treatment relationship between objective cough frequency and work productivity and activity among patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, and unexplained chronic cough.
Work productivity and activity is measured using the Work Productivity and Activity Impairment Questionnaire which is a 6-item self-administered questionnaire used to assess productivity and impairment because of a specific health problem such as chronic cough.
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation in exhaled nitric oxide, blood eosinophils, and sputum eosinophils and objective cough frequency and subjective patient reported outcomes
Time Frame: 3 months
|
Correlations between exhaled nitric oxide, blood eosinophils, and sputum eosinophils and objective cough frequency and subjective patient reported outcomes pre- and post-treatment in patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, unexplained chronic cough.
|
3 months
|
Changes in the quality of life
Time Frame: 3 months
|
Changes in the quality of life, measured using the Leicester Cough Questionnaire pre- and post-treatment in patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, unexplained chronic cough.The Leicester Cough Questionnaire is a 7 point Likert scale with a minimum value of 1 indicating chronic cough impacts participant life all of the time and a maximum value of 7 indicating chronic cough impacts participant life none of the time.
|
3 months
|
Changes in the perceived disease
Time Frame: 3 months
|
Changes in perceived disease improvement, measured using the Global Rating of Change Scale, pre- and post-treatment in patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, unexplained chronic cough.
The Global Rating of Change Scale is a 15 point scale with a minimum value of -7 indicating a worse outcome and a maximum value of +7 indicating a better outcome.
|
3 months
|
Correlations between improved quality of life and perceived disease improvement
Time Frame: 3 months
|
Correlations between improved quality of life, measured using the Leicester Cough Questionnaire, and perceived disease improvement, measure using the Global Rating of Change Scale, pre- and post-treatment in patients referred to secondary care for treatment of explained chronic cough, refractory chronic cough, unexplained chronic cough.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Imran Satia, MD, PhD, McMaster University
Publications and helpful links
General Publications
- Sadatsafavi M, Rousseau R, Chen W, Zhang W, Lynd L, FitzGerald JM. The preventable burden of productivity loss due to suboptimal asthma control: a population-based study. Chest. 2014 Apr;145(4):787-793. doi: 10.1378/chest.13-1619.
- Song WJ, Chang YS, Faruqi S, Kim JY, Kang MG, Kim S, Jo EJ, Kim MH, Plevkova J, Park HW, Cho SH, Morice AH. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015 May;45(5):1479-81. doi: 10.1183/09031936.00218714. Epub 2015 Feb 5. No abstract available.
- Irwin RS, Baumann MH, Bolser DC, Boulet LP, Braman SS, Brightling CE, Brown KK, Canning BJ, Chang AB, Dicpinigaitis PV, Eccles R, Glomb WB, Goldstein LB, Graham LM, Hargreave FE, Kvale PA, Lewis SZ, McCool FD, McCrory DC, Prakash UBS, Pratter MR, Rosen MJ, Schulman E, Shannon JJ, Hammond CS, Tarlo SM. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1 Suppl):1S-23S. doi: 10.1378/chest.129.1_suppl.1S. No abstract available.
- Morice AH, Kastelik JA. Cough. 1: Chronic cough in adults. Thorax. 2003 Oct;58(10):901-7. doi: 10.1136/thorax.58.10.901.
- Pratter MR. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1 Suppl):59S-62S. doi: 10.1378/chest.129.1_suppl.59S.
- Andreasson E, Svensson K, Berggren F. PRP11 The validity of the work productivity and activity impairment questionnaire for patients with asthma (WPAIASTHMA): Results from a web-based study. Value in Health. 2003;6(6):780.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 59689
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Mayo ClinicRecruitingRefractory Chronic CoughUnited States
-
Stuart MazzoneMelbourne Health; Merck Sharp & Dohme LLC; Monash UniversityNot yet recruitingChronic CoughAustralia
-
ShionogiCompletedChronic CoughUnited States, United Kingdom, Japan, Ukraine, Poland, Czechia
-
Respivant Sciences GmbHRespivant Sciences Inc.TerminatedChronic Cough | IPF | Persistent Cough in IPFUnited States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
-
Genentech, Inc.RecruitingChronic Refractory Cough (CRC) With Non-atopic Asthma | CRC With Atopic Asthma | Unexplained Chronic Cough | CRC With Chronic Obstructive Pulmonary Disease | CRC With Chronic Obstructive Pulmonary Disease With Chronic BronchitisUnited States, Australia, United Kingdom, Canada
-
Merck Sharp & Dohme LLCCompletedChronic CoughCanada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
-
Hull University Teaching Hospitals NHS TrustRecruitingChronic CoughUnited Kingdom
-
Imperial College LondonMerck Sharp & Dohme LLCRecruitingChronic CoughUnited Kingdom
Clinical Trials on Usual clinical practice
-
Consorci Sanitari de l'Alt Penedès i GarrafCompletedFull-term Newborn BabiesSpain
-
University of MalagaKing's College LondonWithdrawnMild Cognitive ImpairmentSpain
-
University of MalagaKing's College LondonRecruiting
-
Hospital San Carlos, MadridNot yet recruitingKidney Transplant; ComplicationsSpain
-
Institut Investigacio Sanitaria Pere VirgiliUniversity Rovira i Virgili; Hospital Universitari Joan XXIII de Tarragona.; Hospital...Active, not recruitingMicrobial ColonizationSpain
-
Gerencia de Atención Primaria, MadridFondo de Investigacion Sanitaria; Instituto de Salud Carlos IIICompletedPerimenopausal WomenSpain
-
Azienda Ospedaliero Universitaria Maggiore della...Not yet recruiting
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Catalan Society of Family Medicine; Comité Nacional Prevención Tabaquismo; Unitat...UnknownTobacco Smoke PollutionSpain
-
University of North Carolina, Chapel HillCompletedPelvic Organ ProlapseUnited States
-
Malmö UniversitySkane University HospitalCompletedVascular Diseases | Intermittent ClaudicationSweden